Events & News

We are so happy to get back out on the road! Although some conferences and events remain virtual, more and more are opening up and we are running back with open arms! We hope to see you soon!

Please see below for our events and news

Events


2022 CPCA Financial Conference – San Deigo, CA

May 17 -20, 2022


2022 ECRM Health System/Institutional Pharmacy Program Conference – Charlotte, NC

June 15 -17, 2022


2022 FACHC Annual Conference – Fort Lauderdale, FL

July 17 -20, 2022


340B Summer Conference – Washington, DC

August 1 -3, 2022


NACHC CHI – Chicago, IL

August 28-30, 2022


NACHC FOM/IT – Chicago, IL

November 1-2, 2022


News


AstraZeneca Pricing Issues

In early April, 340Basics noticed a significant increase in issues with AstraZeneca drug pricing, seeing that AstraZeneca pushed a bad file to wholesalers to update their systems regarding pricing restrictions for our accounts.


Gilead Announces 340B Contract Pharmacy Restrictions

Gilead recently imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.  Click below to read more on this policy.


340B Registration period is here! April 1st – 15th

Registration with OPAIS occurs four times a year between the first and 15th days of January, April, July and October, for both covered entities and contract pharmacies. Once registered and approved, an entity will be recognized as being active the first day of the following quarter.


Watch the recording of our Webinar: 2021: A Defining Year for 340B – What Developed, Actions Taken and What’s to Come


340Basics releases cutting-edge reporting tool inside their 340B Applications

October 2021

Managing a 340B Program can prove to be difficult, with an abundance of data and information to analyze, 340Basics has taken the guess work out of it…learn more


340Basics is awarded the 2021 GHP – Best Healthcare Software Solution in US

July 2021

We are humbled and exited to accept this global award recognizing our drive and dedication to create the best technology solution in the market…


340Basics hosted joint 340B advocacy webinar with powerful 340B players

May 2021

Hear from those “on the ground” to hear what’s next for New York and to learn how you too can fight back against such proposals if a “carve out” is proposed in your state. Watch Webinar Here.

Share your concerns,

we'll deliver solutions.

Industry-Leading 340B Software Solutions
Covered Entity & Pharmacy Expertise
Exceptional 340B Education & Support

Contact our team today.

GET IN TOUCH WITH US FOR THE NEXT EVENT

AstraZeneca Pricing Issues


In early April, 340Basics noticed a significant increase in issues with AstraZeneca drug pricing, seeing that AstraZeneca pushed a bad file to wholesalers to update their systems regarding pricing restrictions for our accounts. This caused accounts with exceptions to be blocked and sent to us at retail pricing instead of 340B pricing. The file was likely sent from AstraZeneca to wholesalers at the end of March/beginning of April. Price files for our accounts were incorrect as of 4/2, but wholesalers are indicating that the pricing is reflecting correctly on their end, likely meaning AstraZeneca corrected the errors with an updated file sent to wholesalers after 4/2. 340Basics has not seen all accounts updated with new files to confirm and are working to request updates on affected accounts ASAP. If you have an account affected by this and wish to ensure new files are received, please contact us here: https://340basics.com/contact-us/

Gilead Announces 340B Contract Pharmacy Restrictions

Gilead recently imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. The policy, which applies to hospital and grantee entities, comes in the same week that entities became aware of an apparent change in Gilead’s HIV drug reimbursement practices, giving contract pharmacies second thoughts on whether they want to continue to partner with 340B providers. Hospitals and grantees reported receiving a March 15 letter by email stating that starting May 2, 340B covered entities must provide claims level data for Gilead’s branded hepatitis C products to remain eligible for bill to/ship to orders for multiple contract pharmacies.

This past year, Covered Entities participating in the 340B program in New York state fought against the state’s efforts to “carve out” the pharmacy benefit, moving it from managed care to fee-for-service. That action would have decimated the 340B program for safety net providers and vulnerable populations they serve. RWC-340B worked closely with Save New York’s Safety Net (SNYSN) in a coordinated campaign that eventually achieved a two year delay in the proposed policy.

Hear from those “on the ground” to hear what’s next for New York and to learn how you too can fight back against such proposals if a “carve out” is proposed in your state.

Speakers Include:

  • Mark Malahosky, Trillium Health/RWC-340B
  • Mike Lee, Evergreen/RWC-340B
  • Kimberleigh Smith, Callen-Lorde/Save New York’s Safety Net
  • Peggy Tighe, Powers Law Firm/RWC-340B/CV340B
  • Colleen DiClaudio (CV340B Board member/340Basics) serving as moderator